From Amyloidosis Foundation
A recent 15-year analysis from ashpublications.org reveals a significant decline (71%) in autologous stem cell transplantation (ASCT) for AL amyloidosis as Dara-CyBorD (daratumumab, cyclophosphamide, bortezomib, dexamethasone) replaced CyBorD (cyclophosphamide, bortezomib, dexamethasone) as the preferred upfront therapy. The study indicates ASCT is now reserved for patients with relapsed/refractory disease, suboptimal responses to Dara-CyBorD, or high bone marrow plasma cell burden.
Key Findings:
Shift from ASCT to Dara-CyBorD:
.
The introduction of Dara-CyBorD led to a substantial decrease in ASCT utilization, with a 71% reduction observed between the CyBorD-dominated era (2010-2019) and the Dara-CyBorD era (2020-2024).
Increased Pre-ASCT Therapy:
.
In the more recent cohort, a higher percentage of patients received pre-ASCT induction therapy, with Dara-CyBorD being the prevalent choice.
Improved Response Rates:
.
Dara-CyBorD demonstrated superior hematologic response rates compared to CyBorD, contributing to its reduced reliance on ASCT as a salvage therapy.
ASCT for Refractory/High-Risk Cases:
.
ASCT is now primarily utilized for patients who don't respond adequately to Dara-CyBorD, patients with relapsed or refractory disease, or those with a "myeloma phenotype" characterized by a high plasma cell burden in the bone marrow.
Patient Profile Changes:
.
The study also noted some changes in the characteristics of patients undergoing ASCT in the later period, including older age and a higher baseline bone marrow plasma cell burden.

Your Feed
Filter by
See content from
Playlist: Physical Activity - Exercise and Sleep
What are the main components of a well balanced fitness routine for individuals living with myeloma?
Video details & playlist
Playlist: Physical Activity - Exercise and Sleep
Role of Sleep to Myeloma Patients
Video details & playlist
Playlist: Building Your Healthcare Team
What is palliative care and how does it differ from hospice care?
Video details & playlist
Playlist: Chromosomal and Gene Abnormalities in Myeloma
Will chromosomal abnormalities go away after an autologous stem cell transplant?
Video details & playlist
Playlist: Relapsed and Refractory MM Treatment
Will an allogeneic transplant ever be considered at relapse?
Video details & playlist
Playlist: Chromosomal and Gene Abnormalities in Myeloma
What do I need to know about TP53 the gene?
Video details & playlist
Playlist: Chromosomal and Gene Abnormalities in Myeloma
If deletion 17 p is not detected at diagnosis, can it develop later in myeloma?
Video details & playlist


